Shares in Addex Therapeutics Ltd. (Zurich:ADXN) dropped 48% June 17 on news that the company had terminated a pivotal phase IIb/III study of dipraglurant as a potential treatment for dyskinesia in Parkinson’s disease.
LONDON – In the rush to test drugs against COVID-19, clinical trials in other indications are starting to be interrupted by the strains on health care systems and the fact that many potential patients are those most at risk from the effects of the novel coronavirus.